Health Boards
Bimzelx better than Skyrizi in psoriatic arthritis first head to head study.
Source: ucb.com
Bimzelx (bimekizumab)
Skyrizi (risankizumab)
- Primary endpoint showing superiority met: Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity, as measured by the stringent ACR50 endpoint, at Week 16 in adults living with active psoriatic arthritis
- Landmark psoriatic arthritis (PsA) study: Bimekizumab is the first licensed biologic therapy to demonstrate superiority in psoriatic arthritis over an IL-23 inhibitor
- Fourth bimekizumab study showing superiority: BE BOLD is the fourth head-to-head study demonstrating superiority in the bimekizumab clinical trial program across psoriatic disease, and the first conducted in PsA
Quote:
UCB today announced positive topline data from the BE BOLD trial assessing Bimzelx (bimekizumab) versus Skyrizi (risankizumab) in adults living with active psoriatic arthritis (PsA). Bimekizumab, the first and only approved medicine to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), demonstrated statistically significant superiority in the ACR50 primary efficacy endpoint at Week 16. Treatment with bimekizumab was generally well tolerated, with no new safety signals observed to Week 16.
“Our landmark BE BOLD study provides the first head-to-head evidence of superiority versus an IL-23 inhibitor in psoriatic arthritis. These topline results reinforce bimekizumab’s potential to deliver clinically meaningful improvements using the stringent ACR50 measure of disease activity, indicating more complete control of joint inflammation,” said Emmanuel Caeymaex, Executive Vice President, Head of Patient Evidence, UCB. “BE BOLD represents the fourth head-to-head study demonstrating bimekizumab superiority, supporting physicians to make informed treatment decisions and advancing our ambitions to raise the standard of care for people living with psoriatic disease.”
The results of BE BOLD add to the breadth of data for bimekizumab across a range of immune-mediated inflammatory diseases.
Source: ucb.com
Bimzelx (bimekizumab)
Skyrizi (risankizumab)
